Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

“…This combination was further evaluated in a phase II study conducted by Holloway and colleagues in which patients Rose 212 received gemcitabine 650 mg/m 2 on days 1 and 8 and pegylated liposomal doxorubicin 25 mg/m 2 on day 1 every 21 days (pegylated liposomal doxorubicin dose intensity, 8.3 mg/m 2 weekly) [40]. Most patients enrolled in this study (17/25) had platinumsensitive disease.…”

Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems

“…Liposomal doxorubicin, an FDA approved drug has been shown to inhibit both taxane- and platinum-sensitive and resistant recurrent ovarian cancers [52, 53]. In one study it was demonstrated that Doxil, as a single-agent, reduced recurrent ovarian carcinoma with a ∼25% response rate [54]. In another phase II open label study administration of 50 mg/m2, every 4 weeks Doxil yielded partial response in 7 of 34 (20.6%) advanced refractory epithelial ovarian cancer patients [53, 55, 56].…”

Review of gemcitabine-based combinations for platinum-resistant ovarian cancer

“…At the 40th Annual Meeting of the American Society of Clinical Oncology in 2004, Holloway et al reported their experiences with pegylated liposomal doxorubicin (25 mg/m 2 ) on day 1 combined with gemcitabine (650 mg/m 2 ) on days 1 and 8 every 3 weeks (44) . Twenty-five patients who had recurrent ovarian cancer and had received prior treatment with carboplatin and paclitaxel were enrolled in this phase II trial.…”